{"id":107629,"date":"2021-02-08T09:48:43","date_gmt":"2021-02-08T02:48:43","guid":{"rendered":"http:\/\/nawacita.co\/?p=107629"},"modified":"2021-02-08T09:48:43","modified_gmt":"2021-02-08T02:48:43","slug":"vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia","status":"publish","type":"post","link":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/","title":{"rendered":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia"},"content":{"rendered":"<p><a href=\"https:\/\/nawacita.co\"><strong>Surabaya | Nawacita<\/strong><\/a> &#8211; BPOM resmi menyetujui vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar 2.551.472 lansia. Lalu kapan proses vaksinasi untuk lansia?<\/p>\n<p>&#8220;Lansia nanti rencananya masuk tahap ke-2 bersama petugas pelayanan publik, TNI, Polri, ASN,&#8221; ujar Jubir Satgas COVID-19 Jatim, dr Makhyan Jibril kepada detikcom, Senin (8\/2\/2021).<\/p>\n<p>Untuk detail waktunya sendiri, Jibril menyebut akan dilakukan secepatnya akhir Februari 2021. Namun, proses\u00a0vaksinasi\u00a0lansia yang masuk tahap ke-2, harus menunggu proses vaksinasi nakes selesai.<\/p>\n<p>&#8220;Insya Allah akhir Februari setelah nakes, baru dimulai tahap ke-2, setelah vaksin selanjutnya datang. Karena dosis vaksin dua termin ini untuk nakes, dan masih perlu kiriman lagi,&#8221; imbuhnya.<\/p>\n<p>Jibril menjelaskan, para lansia berumur 60 tahun ke atas sudah dikelompokkan untuk menjadi target sasaran di Jatim.<\/p>\n<p>&#8220;Sudah (jadi sasaran vaksinasi). Sejak awal kan sudah kita kelompokkan, berapa jumlahnya, untuk sasaran\u00a0lansia\u00a0ini,&#8221; ujar Jibril kepada detikcom, Minggu (7\/2\/2021).<\/p>\n<p><strong>Baca Juga :\u00a0<a href=\"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/hari-ini-vaksinasi-covid-19-untuk-nakes-lansia-dimulai\/\">Hari Ini, Vaksinasi Covid-19 Untuk Nakes Lansia Dimulai<\/a><\/strong><\/p>\n<p>Untuk jumlahnya, Jibril menyebut ada sekitar 2.551.472 lansia yang masuk target sasaran vaksinasi di Jatim. Untuk waktu pelaksanaan\u00a0vaksin, Jibril masih menunggu arahan Gubernur Jatim.<\/p>\n<p>&#8220;EUA (Emergency Use Authorization) vaksin Sinovac untuk usia lanjut sudah dirilis oleh BPOM. Tentu untuk pelaksanaannya masuk tahapan ke berapa, masih menunggu arahan lebih lanjut dari Ibu Gubernur dan tentunya pemerintah pusat,&#8221; jelasnya.<\/p>\n<div class=\"clearfix\">&#8220;Kalau untuk berapa jumlah sasarannya, kita sudah targetkan sejak awal sekitar 2,5 juta lebih lansia di Jatim,&#8221; lanjutnya.<\/div>\n<div class=\"parallax_detail parallaxB\">\n<div class=\"parallax_abs\">\n<div class=\"parallax_fix\">\n<div><\/div>\n<\/div>\n<\/div>\n<\/div>\n<p>Sebelumnya BPOM resmi menyetujui vaksin COVID-19 untuk lansia di atas 60 tahun. Dalam lampiran Pusat Informasi Obat Nasional (PIONAS) vaksin Sinovac oleh BPOM, tertulis untuk lansia usia 60 tahun atau lebih, vaksin akan disuntikkan ke dalam otot (intramuskular) sebanyak 0,5 mL dalam dua dosis dengan selang waktu 28 hari.<\/p>\n<p>&#8220;Betul BPOM telah memberikan persetujuan untuk lansia,&#8221; kata juru bicara vaksinasi COVID-19 BPOM, Dra Lucia Rizka Andalusia, kepada detikcom, Minggu (7\/2\/2021).<\/p>\n<p><strong>Baca Juga :\u00a0<a href=\"https:\/\/nawacita.co\/index.php\/2021\/01\/12\/akhirnya-bpom-keluarkan-izin-vaksin\/\">Akhirnya BPOM Keluarkan Izin Vaksin<\/a><\/strong><\/p>\n<p><em><strong>Sebelum vaksinasi, lansia juga diharapkan melaporkan ke petugas kesehatan jika mengalami:<\/strong><\/em><\/p>\n<p>&#8211; Kesulitan untuk naik 10 anak tangga<br \/>\n&#8211; Penurunan aktivitas fisik (sering merasa kelelahan)<br \/>\n&#8211; memiliki 4 dari 11 penyakit (Hipertensi, diabets, kanker selain kanker kulit kecil), penyakit paru kronis, serangan jantung, gagal jantung kongestif, nyeri dada, asma nyeri sendi, stroke dan penyakit ginjal)<br \/>\n&#8211; Mengalami kesulitan berjalan kira-kira 100 sampai 200 meter<br \/>\n&#8211; Penurunan berat badan yang bermakna dalam setahun<\/p>\n<p><strong>Dtk<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Surabaya | Nawacita &#8211; BPOM resmi menyetujui vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar 2.551.472 lansia. Lalu kapan proses vaksinasi untuk lansia? &#8220;Lansia nanti rencananya masuk tahap ke-2 bersama petugas pelayanan publik, TNI, Polri, ASN,&#8221; ujar Jubir Satgas COVID-19 Jatim, dr Makhyan Jibril kepada [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":107630,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[29694],"tags":[173,5301,18817,30063],"class_list":{"0":"post-107629","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-jatim","8":"tag-jatim","9":"tag-lansia","10":"tag-target","11":"tag-vaksin"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita<\/title>\n<meta name=\"description\" content=\"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita\" \/>\n<meta property=\"og:description\" content=\"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/\" \/>\n<meta property=\"og:site_name\" content=\"Nawacita\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-08T02:48:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1039\" \/>\n\t<meta property=\"og:image:height\" content=\"607\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"redaksi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:site\" content=\"@nawacit4\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"redaksi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/\"},\"author\":{\"name\":\"redaksi\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/person\\\/599683af640858fd3b790bc37828ba57\"},\"headline\":\"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia\",\"datePublished\":\"2021-02-08T02:48:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/\"},\"wordCount\":378,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/vaksisnsgat.jpg\",\"keywords\":[\"jatim\",\"Lansia\",\"Target\",\"vaksin\"],\"articleSection\":[\"JATIM\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/\",\"url\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/\",\"name\":\"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/vaksisnsgat.jpg\",\"datePublished\":\"2021-02-08T02:48:43+00:00\",\"description\":\"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/vaksisnsgat.jpg\",\"contentUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/02\\\/vaksisnsgat.jpg\",\"width\":1039,\"height\":607,\"caption\":\"dr Makhyan Jibril\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/2021\\\/02\\\/08\\\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nawacita.co\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#website\",\"url\":\"https:\\\/\\\/nawacita.co\\\/\",\"name\":\"Nawacita\",\"description\":\"Berita Kementerian, BUMN, Pemerintah dan Politik\",\"publisher\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nawacita.co\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#organization\",\"name\":\"Nawacita\",\"url\":\"https:\\\/\\\/nawacita.co\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Logo-Nawacita-2021.png\",\"contentUrl\":\"https:\\\/\\\/nawacita.co\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/Logo-Nawacita-2021.png\",\"width\":1676,\"height\":422,\"caption\":\"Nawacita\"},\"image\":{\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/nawacitaco-1763136813898723\\\/?ref=aymt_homepage_panel\",\"https:\\\/\\\/x.com\\\/nawacit4\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nawacita.co\\\/#\\\/schema\\\/person\\\/599683af640858fd3b790bc37828ba57\",\"name\":\"redaksi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g\",\"caption\":\"redaksi\"},\"sameAs\":[\"nawacitaportal\",\"https:\\\/\\\/x.com\\\/nawacit4\"],\"url\":\"https:\\\/\\\/nawacita.co\\\/index.php\\\/author\\\/redaksi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita","description":"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/","og_locale":"en_US","og_type":"article","og_title":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita","og_description":"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.","og_url":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/","og_site_name":"Nawacita","article_publisher":"https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","article_published_time":"2021-02-08T02:48:43+00:00","og_image":[{"width":1039,"height":607,"url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","type":"image\/jpeg"}],"author":"redaksi","twitter_card":"summary_large_image","twitter_creator":"@nawacit4","twitter_site":"@nawacit4","twitter_misc":{"Written by":"redaksi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#article","isPartOf":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/"},"author":{"name":"redaksi","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57"},"headline":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia","datePublished":"2021-02-08T02:48:43+00:00","mainEntityOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/"},"wordCount":378,"commentCount":0,"publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","keywords":["jatim","Lansia","Target","vaksin"],"articleSection":["JATIM"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/","url":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/","name":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia - Nawacita","isPartOf":{"@id":"https:\/\/nawacita.co\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#primaryimage"},"image":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#primaryimage"},"thumbnailUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","datePublished":"2021-02-08T02:48:43+00:00","description":"vaksin COVID-19 buatan China, Sinovac Life Sciences Co Ltd. untuk lansia di atas 60 tahun. Jatim sendiri menyasar menyasar 2.551.472 lansia.","breadcrumb":{"@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#primaryimage","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","width":1039,"height":607,"caption":"dr Makhyan Jibril"},{"@type":"BreadcrumbList","@id":"https:\/\/nawacita.co\/index.php\/2021\/02\/08\/vaksin-bersama-pelayanan-publik-tahap-ke-2-jatim-target-25-juta-lansia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nawacita.co\/"},{"@type":"ListItem","position":2,"name":"Vaksin Bersama Pelayanan Publik Tahap ke-2, Jatim Target 2,5 Juta Lansia"}]},{"@type":"WebSite","@id":"https:\/\/nawacita.co\/#website","url":"https:\/\/nawacita.co\/","name":"Nawacita","description":"Berita Kementerian, BUMN, Pemerintah dan Politik","publisher":{"@id":"https:\/\/nawacita.co\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nawacita.co\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/nawacita.co\/#organization","name":"Nawacita","url":"https:\/\/nawacita.co\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/","url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","contentUrl":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/10\/Logo-Nawacita-2021.png","width":1676,"height":422,"caption":"Nawacita"},"image":{"@id":"https:\/\/nawacita.co\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/nawacitaco-1763136813898723\/?ref=aymt_homepage_panel","https:\/\/x.com\/nawacit4"]},{"@type":"Person","@id":"https:\/\/nawacita.co\/#\/schema\/person\/599683af640858fd3b790bc37828ba57","name":"redaksi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a3ea3038dabe75a981e9a69b300b8272c74e0729c55e2f30478cde7add6c42f6?s=96&d=mm&r=g","caption":"redaksi"},"sameAs":["nawacitaportal","https:\/\/x.com\/nawacit4"],"url":"https:\/\/nawacita.co\/index.php\/author\/redaksi\/"}]}},"jetpack_featured_media_url":"https:\/\/nawacita.co\/wp-content\/uploads\/2021\/02\/vaksisnsgat.jpg","_links":{"self":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/107629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/comments?post=107629"}],"version-history":[{"count":0,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/posts\/107629\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media\/107630"}],"wp:attachment":[{"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/media?parent=107629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/categories?post=107629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nawacita.co\/index.php\/wp-json\/wp\/v2\/tags?post=107629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}